Lenalidomide in Diffuse Large B-Cell Lymphomas

  title={Lenalidomide in Diffuse Large B-Cell Lymphomas},
  author={Annalisa Chiappella and Umberto Vitolo},
  booktitle={Advances in hematology},
Diffuse Large B-cell Lymphomas (DLBCL) are the most frequent Non-Hodgkin Lymphomas (NHL). The addition of Rituximab to the standard chemotherapy CHOP improved the outcome in this patients, but so far 40% of patients experienced relapse or progressive disease. Lenalidomide, an immunomodulatory agent, had direct tumoricidal and antiangiogenetic actions on tumor cells and was able to modulate tumor-cell microenvironment, with the restoration of impaired T-cell activity and the formation of immuno… CONTINUE READING